Common Questions From Patients About Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The dialogue revolves around patient education regarding biosimilar medications, focusing on common questions and concerns raised by patients and healthcare providers. Cost emerges as a primary concern for patients, with inquiries centered on out-of-pocket expenses and affordability. Providers emphasize the importance of addressing cost-related anxieties to ensure patient access and adherence to treatment.

Furthermore, patients often express apprehension about the efficacy and safety of biosimilars compared to originator drugs. Providers aim to alleviate these concerns by providing comprehensive education on the data supporting biosimilar efficacy and safety, highlighting studies and addressing questions about immunogenicity and device changes.

Another key discussion point is the management of patients who report problems after switching to biosimilars. Providers stress the need for thorough evaluation to differentiate between true treatment failure and potential psychological factors influencing patient perception. Strategies include objective assessment of disease activity and consideration of alternative treatment options based on clinical evidence.

Overall, the dialogue underscores the importance of patient-centered communication, comprehensive education, and evidence-based decision-making to optimize the transition to biosimilar medications while ensuring patient satisfaction and therapeutic success.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.